Combination treatment before and after surgery for high-risk bile duct cancer
Part of Cancer clinical trials.
This trial tests a new drug combination—cisplatin, gemcitabine (standard chemotherapy), and rilvegostomig (an immunotherapy)—given before and after surgery for a specific type of liver cancer called intrahepatic cholangiocarcinoma. The goal is to reduce the chance of the cancer coming back after surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years of age or older.
- You have been diagnosed with intrahepatic cholangiocarcinoma (bile duct cancer that starts in the liver).
- Your cancer has at least one high-risk feature (such as being larger than 5 cm, having multiple liver tumors, or having cancer in blood vessels or nearby lymph nodes).
- Your cancer is considered removable with surgery, and you have not had any prior treatment for it.
- Your overall health is good (able to do most daily activities), and your organs (like kidneys and liver) are working well enough.
- You do not have cirrhosis with severe liver damage, uncontrolled infections, or other active cancers.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a combination of two drugs (one that helps the immune system fight cancer and one that blocks blood vessel growth) with a special chemotherapy given directly into the liver. The goal is to shrink the tumor so it can be removed with surgery, possibly improving the chances of a cure.
This trial tests a combination of targeted therapy, immunotherapy, and a liver-directed procedure (like chemoembolization) versus a standard chemotherapy cocktail for a type of bile duct cancer that is confined to the liver. It aims to see if the new combo can help patients live longer or slow the cancer down.
This trial tests whether adding an immunotherapy drug (toripalimab) to standard chemotherapy before surgery can improve outcomes for people with intrahepatic cholangiocarcinoma that can be surgically removed. It's for patients who haven't had prior treatment for their cancer and are in good overall health.
This study tests additional treatment given after surgery to remove high-risk intrahepatic cholangiocarcinoma (a type of bile duct cancer). The goal is to reduce the chance the cancer comes back and improve survival in patients whose tumors had concerning features.
This trial studies giving a special internal radiation treatment along with capecitabine (a chemotherapy) for liver cancer related to bile ducts, after planned surgical removal. It may help improve control of the cancer in cases where surgeons think the edges of the removed tumor may be too close.
This trial tests whether adding an immunotherapy drug (rilvegostomig) to standard chemotherapy before surgery can improve outcomes for patients with early-stage bile duct cancer that can be completely removed. The treatment aims to shrink the tumor and help prevent the cancer from coming back.
Hear when a new Intrahepatic Cholangiocarcinoma (Icc) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.